Multicentric experience on the acute effect of nomifensine in hyperprolactinemic women

F. Minuto, A. Barbarino, G. Baviera, G. Mazzocchi, L. De Marinis, R. Leonardi, D. Bernasconi, E. Menini, G. Maira, C. Anile, M. Giusti, G. Giordano

Research output: Contribution to journalArticlepeer-review


The inhibitory effect of nomifensine (Norn; 200 mg orally) on prolactin (PRL) secretion was studied in 15 subjects with puerperal hyperprolactinemia and in 59 pathologic hyperprolactinemic women. The latter were grouped as follows: i) patients with surgically proven PRL secretory pituitary adenomas (proven tumors; 27 cases); ii) patients presenting radiological signs of sella indicative of a pituitary tumor (presumptive tumors; 10 cases); iii) subjects with non-drug induced hyperprolactinemia (hyperprolactinemia of uncertain etiology; 22 cases). A mean PRL fall of 30% or more of baseline hormone levels in samples collected within the 120–240 min post-treatment interval was adopted to define responsiveness to Norn. In 24 out of 27 subjects with proven tumors and in 9 out of 10 subjects with presumptive tumors Norn did not induce significant variations in PRL secretion. In only 11 % of the patients with surgery-confirmed or highly suspected tumors a hormone decrease greater than 30% was observed. In addition, 13 subjects with hyperprolactinemia of uncertain etiology did not respond to Norn administration. In 5 of these, additional data suggesting the existence of an adenoma were collected. Finally, 3 out of 9 Nom-responder patients presented either a polycystic ovary syndrome or transitory hyperprolactinemia. The finding that hyperprolactinemic women, who did not show clinical or radiological signs of a tumor and patients with highly presumptive or proven pituitary tumors may present comparable responses to Norn, suggests that this pattern may be indicative of an early manifestation of a PRL-secreting adenoma which has yet to evolve. The follow-up of Nom-non-responder hyperprolactinemic subjects who did not show clinical signs of harboring a tumor, is therefore advisable.

Original languageEnglish
Pages (from-to)137-140
Number of pages4
JournalJournal of Endocrinological Investigation
Issue number2
Publication statusPublished - 1984


  • nomifensine test
  • pathologic hyperprolactinemia
  • Prolactin secretion
  • puerperal hyperprolactinemia

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Multicentric experience on the acute effect of nomifensine in hyperprolactinemic women'. Together they form a unique fingerprint.

Cite this